Pfizer is a multinational pharmaceutical company in India spanning vaccines, hospitals, internal medicine and immunology.
pfizerltd.co.inCrawled Nov 17, 2026
Inflammation and Immunology
Pfizer offers career opportunities in pharmaceuticals globally.
job detail
Pfizer provides career opportunities in research, development, and other fields.
Pfizer values diverse perspectives to drive innovation in tackling complex challenges.
Pfizer highlights its mission, values, and culture, emphasizing innovation and collaboration.
Pfizer reports a **65.7% increase in Q2 FY27 net profit to Rs 313.25 crore**, driven by a **Rs 132.06 crore one-time gain**. The company’s revenue grows **13.2% year-over-year**, reflecting strong financial performance in the quarter. The gains stem from non-recurring items, while core operations contribute to revenue expansion.
Pfizer India’s Managing Director Meenakshi Nevatia states that new drugs arrive in India **five to six years** after global approvals, far exceeding delays in other markets. She advocates reducing India’s drug approval timeline to **12–18 months** to align with international standards and improve patient access. The comments highlight systemic inefficiencies in India’s regulatory process for pharmaceuticals.
Pfizer introduces **Elranatamab**, a BCMA-targeted bispecific antibody, in India to treat adult patients with **relapsed or refractory multiple myeloma (RRMM)**. The therapy joins Pfizer’s oncology portfolio as a potential option for late-stage disease management. Regulatory approval follows earlier global studies demonstrating its efficacy in this patient group.
Pfizer selects 14 Indian health-tech startups for ₹60 lakh grants each and 18 months of incubation support through its **INDovation Program**. The initiative aims to foster innovation in India’s healthcare sector by providing funding and mentorship. Startups will receive structured guidance to develop and scale solutions in digital health, diagnostics, or therapeutics.
Cipla secures exclusive rights to market, distribute, and sell four Pfizer pharmaceutical products in India. The brands include cough syrups Corex Dx and Corex LS, the non-steroidal anti-inflammatory drug Dolonex, the proton pump inhibitor Neksium, and the oral antibiotic Dalacin C. The agreement grants Cipla sole responsibility for these products’ commercialization within the country.
Cipla now markets and distributes select Pfizer brands in India under a new partnership agreement. The collaboration expands Cipla’s pharmaceutical distribution network while integrating Pfizer’s product portfolio into its existing reach. Both companies aim to strengthen market presence for the selected brands.
Pfizer India expands parental leave benefits by offering **12 weeks of paternity leave** to employees. The policy aligns with the company’s diversity and inclusion goals, aiming to support work-life balance. This move follows broader industry trends toward equitable family leave policies.
Pfizer India and Max Hospitals have partnered to launch a fellowship programme. The collaboration also aims to establish centres of excellence focused on rare diseases.
Pfizer India and Max Super Speciality Hospitals collaborate to offer fellowships for young doctors at 17 Max hospitals. The program leverages Electronic Patient Records (EPRs) to generate real-world evidence on drug efficacy and proven therapies. Focus areas include prevention, treatment, and management of high-priority diseases like cancer and cardiovascular conditions in India.